HOME >> BIOLOGY >> NEWS
Vion Demonstrates Readiness Of First Tumor-Targeting Salmonella For Human Testing Against Solid Tumors

o inhibit a broad variety of both primarily and metastatic tumors when given systemically. This ability clearly and uniquely distinguishes TAPET from the numerous gene therapy approaches to cancer treatment, all of which require pre-detection of the tumor and local, direct administration of the agent, and thus do not allow for systemic therapy."

"We believe that TAPET vectors represent a novel and exciting approach to the treatment of cancer," said Alan Kessman, Vion chief executive officer. "These organisms, without "warheads", suppress tumor growth in a significant manner on their own, which enhances the even greater potential of using TAPET as a "guided missle" that can be engineered to selectively deliver a wide variety of anticancer agents (so-called "warheads") to solid tumors throughout the body."

Vion's TAPET vectors are Salmonella bacteria whose potential for virulence and the ability to cause septic shock are enormously reduced through the use of highly stable genetic modifications. Research reported in the January issue of Nature Biotechnology showed that the TAPET organisms' ability to trigger TNF-alpha and cause death in animal models was reduced by 10,000 fold. At the same time, the TAPET organisms retained their high selectivity for tumors over normal tissues. In addition, the TAPET organisms remained fully sensitive to a wide range of antibiotics, adding a further level of safety and control to their potential use as anticancer agents.


'"/>

Contact: Joan Kureczka
jkureczka@aol.com
415-821-2413
Kureczka/Martin Associates
11-Apr-1999


Page: 1 2 3

Related biology news :

1. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
2. Engineering Animation, Inc. Demonstrates Internet Anatomy At Visible Human Project Conference
3. Study Demonstrates High Conservation Potential Of Logged Rainforest
4. First glimpse of DNA binding to viral enzyme
5. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
6. 2nd media alert First Scientific Conference on Childhood Leukaemia
7. First International Scientific Conference on Childhood Leukaemia
8. First ever standards linking climate change, biodiversity and poverty seek global peer review
9. First genetic comparison of purebred domestic dogs produces surprises
10. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
11. First target for childhood malaria vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: